不稳定穿支动脉梗死患者在静脉溶栓24h内应用替罗非班的有效性和安全性  

Efficacy and Safety of Tirofiban in Patients with Unstable Perforator Artery Infarction within 24h of Intravenous Thrombolysis

作　　者：杜伟伟 赵昆 贾永林 DU Wei-wei;ZHAO Kun;JIA Yong-lin(Department of Neurology,Kaifeng Central Hospital,Kaifeng 475000,Henan Province,China)

机构地区：[1]开封市中心医院神经内科,河南开封475000

出　　处：《罕少疾病杂志》2024年第9期25-27,共3页Journal of Rare and Uncommon Diseases

基　　金：开封市卫健委项目(2203060)。

摘　　要：目的 探讨替罗非班治疗不稳定穿支动脉梗死患者的效果及不良事件发生情况。方法 选取2021年1月至2023年5月在开封市中心医院神经内科就诊的不稳定穿支动脉梗死患者52例。静脉溶栓治疗24h内予以替罗非班治疗的患者纳入替罗非班组,否则均纳入非替罗非班组。对比两组基线资料、神经功能及不良事件。结果 两组基线资料比较,P>0.05;替罗非班组治疗1周时NIHSS评分、治疗90dm Rs评分均低于非替罗非班组(P<0.05),预后良好率高于非替罗非班组(P<0.05);两组不良事件发生情况比较,P>0.05。结论 替罗非班治疗不稳定穿支动脉梗死患者能够显著改善患者的神经功能,且在治疗90天后的功能独立性评分较非替罗非班组更为优越,此外,尽管两组不良事件发生率无显著差异,但替罗非班组的安全性未见明显增加,提示其在临床应用中的可行性。Objective To investigate the efficacy and adverse events of tirofiban in the treatment of patients with unstable perforator artery infarction.Methods 52 patients with unstable perforator artery infarction who were admitted to the Department of Neurology,Kaifeng Central Hospital from January 2021 to May 2023 were selected.Patients who were treated with tirofiban within 24 hours of intravenous thrombolysis were included in the tirofiban group,otherwise were included in the non-tirofiban group.The baseline data,neurological function and adverse events were compared between the two groups.Results The baseline data of the two groups were compared,P>0.05.The NIHSS score at 1 week of treatment,the mRs Score at 90 days of treatment,and the rate of good prognosis in the tirofiban group were higher than those in the non-tirofiban group(P<0.05).The incidence of adverse events was compared between the two groups,P>0.05.Conclusions Tirofiban can significantly improve neurological function in patients with unstable perforator artery infarction,and the functional independence score at 90 days after treatment is superior to non-tirofiban group.In addition,although there is no significant difference in the incidence of adverse events between the two groups,tirofiban group has no significant increase in safety,suggesting the feasibility of its clinical application.

关 键 词：不稳定穿支动脉梗死 静脉溶栓 替罗非班 有效性 安全性 

分 类 号：R743.3[医药卫生—神经病学与精神病学]